Comparative Pharmacology
Head-to-head clinical analysis: CHLORPROPAMIDE versus DIABETA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHLORPROPAMIDE versus DIABETA.
CHLORPROPAMIDE vs DIABETA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Stimulates insulin release from pancreatic beta cells by blocking ATP-sensitive potassium channels, increasing intracellular calcium, and enhancing peripheral insulin sensitivity. Also reduces hepatic glucose production.
Glyburide is a sulfonylurea that stimulates insulin secretion from pancreatic beta cells by blocking ATP-sensitive potassium channels, leading to cell depolarization and calcium influx.
Initial: 250 mg orally once daily. Maintenance: 100-500 mg orally once daily.
Initial: 2.5-5 mg orally once daily, titrating to max 20 mg/day in 1-2 divided doses. Maintenance: 5-10 mg/day.
None Documented
None Documented
36 hours (range 25-60 hours). Prolonged in renal impairment due to cumulative effects and hypoglycemia risk.
Clinical Note
moderateChlorpropamide + Gatifloxacin
"Chlorpropamide may increase the hypoglycemic activities of Gatifloxacin."
Clinical Note
moderateChlorpropamide + Rosoxacin
"Chlorpropamide may increase the hypoglycemic activities of Rosoxacin."
Clinical Note
moderateChlorpropamide + Levofloxacin
"Chlorpropamide may increase the hypoglycemic activities of Levofloxacin."
Clinical Note
moderateChlorpropamide + Trovafloxacin
Terminal elimination half-life is approximately 10–12 hours in healthy individuals. Clinically, this supports once-daily dosing; may be prolonged in renal impairment.
Renal excretion of unchanged drug (80-90%) and hepatic metabolites (10-20%). Biliary/fecal excretion is minimal (<5%).
Approximately 50% renal (unchanged drug and metabolites), 50% biliary/fecal. Renal elimination accounts for 50% of dose, with about 20% unchanged and 30% as metabolites. Biliary excretion of metabolites contributes to fecal elimination.
Category C
Category C
Sulfonylurea Antidiabetic
Sulfonylurea Antidiabetic
"Chlorpropamide may increase the hypoglycemic activities of Trovafloxacin."